Nonalcoholic Fatty Liver Disease and HIV Infection

 

 Buy Article Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that includes a range of disorders associated with fatty liver from steatosis to cirrhosis and hepatocellular carcinoma, defined by the presence of liver fat accumulation exceeding 5% of hepatocytes in the absence of other causes of liver disease such as alcohol consumption, viral hepatitis, or any other specific etiology. Half the patients with human immunodeficiency virus (HIV) who undergo additional testing for unexplained liver test abnormalities may suffer from NAFLD, which is the hepatic manifestation of the metabolic syndrome. In HIV-infected patients, NAFLD can result from the HIV itself, highly active antiretroviral therapy (HAART), and/or lipodystrophy. Evaluation of the liver impact of NAFLD remains mainly based on liver biopsy, but numerous noninvasive procedures are under evaluation. In HIV/hepatitis C virus (HCV-) coinfected patients, steatosis seems more frequent and severe by comparison with HCV-monoinfected patients, and is associated with significant liver fibrosis, which may contribute to the more rapid progression of liver disease. First-line treatment of NAFLD is mainly based on the adequate management of the metabolic syndrome, including lifestyle changes. Specific therapeutic approaches are under investigation.

• References

• 1 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37 (5) 1202-1219
  CrossrefPubMedGoogle Scholar
• 2 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
  PubMedGoogle Scholar
• 3 Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19 (2) 221-229
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010; 51 (2) 373-375
  CrossrefPubMedGoogle Scholar
• 5 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (4) 578-584
  CrossrefPubMedGoogle Scholar
• 6 Hui JM, Kench JG, Chitturi S , et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38 (2) 420-427
  PubMedGoogle Scholar
• 7 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5) 1820-1832
  CrossrefPubMedGoogle Scholar
• 8 Joint UN Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition. Executive summary. Available at: http://data.unaids.org/pub/ GlobalReport/2006/2006_gr-executivesummary_en.pdf . Accessed February 9, 2010
  PubMedGoogle Scholar
• 9 Mocroft A, Brettle R, Kirk O , et al; EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16 (12) 1663-1671
  CrossrefPubMedGoogle Scholar
• 10 Weber R, Sabin CA, Friis-Moller N , et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15) 1632-1641
  CrossrefPubMedGoogle Scholar
• 11 Salmon-Ceron D, Lewden C, Morlat P , et al; Mortality 2000 study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42 (6) 799-805
  CrossrefPubMedGoogle Scholar
• 12 Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377 (9772) 1198-1209
  CrossrefPubMedGoogle Scholar
• 13 Hu B, French SW. 2′,3′-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol 1997; 108 (3) 280-283
  PubMedGoogle Scholar
• 14 Coglan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33 (11) 1914-1921
  CrossrefPubMedGoogle Scholar
• 15 Duong Van Huyen JP, Landau A, Piketty C , et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol 2003; 119 (4) 546-555
  CrossrefPubMedGoogle Scholar
• 16 Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology 1998; 114 (4) 842-845
  CrossrefPubMedGoogle Scholar
• 17 Lavoie JM, Gauthier MS. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006; 63 (12) 1393-1409
  CrossrefPubMedGoogle Scholar
• 18 Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19 (4) 291-302
  CrossrefPubMedGoogle Scholar
• 19 Parola M, Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal 2011; 15 (2) 461-483
  CrossrefPubMedGoogle Scholar
• 20 Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25 (4) 672-690
  Google Scholar
• 21 Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9 (3) 299-314
  CrossrefPubMedGoogle Scholar
• 22 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology 2004; 40 (1) 46-54
  CrossrefPubMedGoogle Scholar
• 23 Sanyal AJ, Campbell-Sargent C, Mirshahi F , et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120 (5) 1183-1192
  CrossrefPubMedGoogle Scholar
• 24 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21 (1) 27-41
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37 (1) 56-62
  CrossrefPubMedGoogle Scholar
• 26 Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16 (4) 421-427
  CrossrefPubMedGoogle Scholar
• 27 Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006; 290 (6) G1339-G1346
  CrossrefPubMedGoogle Scholar
• 28 Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006; 291 (2) E275-E281
  CrossrefPubMedGoogle Scholar
• 29 Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42 (6) 928-940
  CrossrefPubMedGoogle Scholar
• 30 Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50 (3) 957-969
  CrossrefPubMedGoogle Scholar
• 31 Marra F. Leptin and liver tissue repair: do rodent models provide the answers?. J Hepatol 2007; 46 (1) 12-18
  PubMedGoogle Scholar
• 32 Aleffi S, Petrai I, Bertolani C , et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42 (6) 1339-1348
  CrossrefPubMedGoogle Scholar
• 33 Jiang JX, Mikami K, Shah VH, Torok NJ. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 2008; 48 (5) 1497-1505
  CrossrefPubMedGoogle Scholar
• 34 Iwai M, Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 2009; 32 (6) 425-427
  CrossrefPubMedGoogle Scholar
• 35 Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 2008; 12 (4) 825-852 , ix
  CrossrefPubMedGoogle Scholar
• 36 Kohlstedt K, Gershome C, Trouvain C, Hofmann WK, Fichtlscherer S, Fleming I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol Pharmacol 2009; 75 (3) 685-692
  CrossrefPubMedGoogle Scholar
• 37 Crum-Cianflone N, Dilay A, Collins G , et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50 (5) 464-473
  CrossrefPubMedGoogle Scholar
• 38 Guaraldi G, Squillace N, Stentarelli C , et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47 (2) 250-257
  CrossrefPubMedGoogle Scholar
• 39 Mohammed SS, Aghdassi E, Salit IE , et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45 (4) 432-438
  CrossrefPubMedGoogle Scholar
• 40 Ingiliz P, Valantin MA, Duvivier C , et al. Liver damage underlying unexplained transaminases elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49 (2) 436-442
  CrossrefPubMedGoogle Scholar
• 41 Marks K, Petrovic L, Talal A , et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192 (11) 1943-1949
  CrossrefPubMedGoogle Scholar
• 42 Laguno M, Milinkovic A, de Lazzari E , et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10 (3) 423-429
  PubMedGoogle Scholar
• 43 Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005; 7 (4) 197-209
  PubMedGoogle Scholar
• 44 Hu KQ, Kyulo NL, Esrailian E , et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40 (1) 147-154
  PubMedGoogle Scholar
• 45 Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36 (3) 729-736
  CrossrefPubMedGoogle Scholar
• 46 Browning JD, Szczepaniak LS, Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6) 1387-1395
  CrossrefPubMedGoogle Scholar
• 47 Rubbia-Brandt L, Quadri R, Abid K , et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33 (1) 106-115
  CrossrefPubMedGoogle Scholar
• 48 Bani-Sadr F, Carrat F, Bedossa P , et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20 (4) 525-531
  CrossrefPubMedGoogle Scholar
• 49 Castéra L, Loko MA, Le Bail B , et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV-monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther 2007; 26 (11-12) 1489-1498
  CrossrefPubMedGoogle Scholar
• 50 McGovern BH, Ditelberg JS, Taylor LE , et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infections in HIV-seropositive patients. Clin Infect Dis 2006; 43 (3) 365-372
  CrossrefPubMedGoogle Scholar
• 51 Neau D, Winnock M, Castéra L , et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. . J Acquir Immune Defic Syndr 2007; 45 (2) 168-173
  CrossrefPubMedGoogle Scholar
• 52 Rodríguez-Torres M, Govindarajan S, Solá R , et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48 (5) 756-764
  CrossrefPubMedGoogle Scholar
• 53 Sterling RK, Contos MJ, Smith PG , et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47 (4) 1118-1127
  CrossrefPubMedGoogle Scholar
• 54 Sulkowski MS, Mehta SH, Torbenson M , et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19 (6) 585-592
  CrossrefPubMedGoogle Scholar
• 55 Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology 2009; 137 (3) 795-814
  CrossrefPubMedGoogle Scholar
• 56 Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44 (6) 1026-1032
  CrossrefPubMedGoogle Scholar
• 57 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52 (3) 71-78
  CrossrefPubMedGoogle Scholar
• 58 Keithley JK, Duloy AM, Swanson B, Zeller JM. HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care 2009; 20 (4) 260-274
  CrossrefPubMedGoogle Scholar
• 59 Amorosa V, Synnestvedt M, Gross R , et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39 (5) 557-561
  PubMedGoogle Scholar
• 60 Lapadula G, Torti C, Paraninfo G , et al; EPOKa-A Study Group of the MASTER Cohort. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006; 11 (4) 521-527
  PubMedGoogle Scholar
• 61 Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34 (3) 428-434
  CrossrefPubMedGoogle Scholar
• 62 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42 (1) 44-52
  CrossrefPubMedGoogle Scholar
• 63 Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25 (8) 883-889
  CrossrefPubMedGoogle Scholar
• 64 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12 (5) 1106-1110
  CrossrefPubMedGoogle Scholar
• 65 Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 2002; 3 (1) 89-98
  PubMedGoogle Scholar
• 66 Worm SW, Friis-Møller N, Bruyand M , et al; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24 (3) 427-435
  CrossrefPubMedGoogle Scholar
• 67 Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42 (2) 310-316
  CrossrefPubMedGoogle Scholar
• 68 Sulkowski M, Mehta S, Montes de Occa R, Moore R, Thomas D. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO
  PubMedGoogle Scholar
• 69 DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re III V. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116
  CrossrefPubMedGoogle Scholar
• 70 Castellares C, Barreiro P, Martín-Carbonero L , et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15 (3) 165-172
  PubMedGoogle Scholar
• 71 Poynard T, Lebray P, Ingiliz P , et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40
  CrossrefPubMedGoogle Scholar
• 72 Paradis V, Perlemuter G, Bonvoust F , et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34 (4 Pt 1) 738-744
  CrossrefPubMedGoogle Scholar
• 73 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 (6) 1356-1362
  CrossrefPubMedGoogle Scholar
• 74 Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci 2008; 53 (3) 785-788
  CrossrefPubMedGoogle Scholar
• 75 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42 (1) 132-138
  CrossrefPubMedGoogle Scholar
• 76 Bhala N, Angulo P, van der Poorten D , et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54 (4) 1208-1216
  CrossrefPubMedGoogle Scholar
• 77 Woreta TA, Sutcliffe CG, Mehta SH , et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140 (3) 809-817
  CrossrefPubMedGoogle Scholar
• 78 Sterling RK, Wegelin JA, Smith PG , et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8 (12) 1070-1076
  CrossrefPubMedGoogle Scholar
• 79 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
  CrossrefPubMedGoogle Scholar
• 80 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344 (7) 495-500
  CrossrefPubMedGoogle Scholar
• 81 Qayyum A, Chen DM, Breiman RS , et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?. Clin Imaging 2009; 33 (2) 110-115
  CrossrefPubMedGoogle Scholar
• 82 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51 (3) 433-445
  CrossrefPubMedGoogle Scholar
• 83 Lee SW, Park SH, Kim KW , et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 2007; 244 (2) 479-485
  CrossrefPubMedGoogle Scholar
• 84 Limanond P, Raman SS, Lassman C , et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004; 230 (1) 276-280
  CrossrefPubMedGoogle Scholar
• 85 Park SH, Kim PN, Kim KW , et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239 (1) 105-112
  CrossrefPubMedGoogle Scholar
• 86 Liu ZJ, Gong JP, Yan LN. Quantitative estimation of the degree of hepatic macrovesicular steatosis in a disease-free population: a single-center experience in mainland China. Liver Transpl 2009; 15 (11) 1605-1612
  CrossrefPubMedGoogle Scholar
• 87 Shores NJ, Link K, Fernandez A , et al. Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Dig Dis Sci 2011; 56 (7) 2145-2151
  CrossrefPubMedGoogle Scholar
• 88 Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46 (3) 312-317
  CrossrefPubMedGoogle Scholar
• 89 Ghotb A, Noworolski SM, Madden E , et al. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010; 55 (2) 228-231
  CrossrefPubMedGoogle Scholar
• 90 Poynard T, Ratziu V, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
  CrossrefPubMedGoogle Scholar
• 91 Zein CO, Edmison JM, Schluchter M, Feldstein AE, Zein NN, McCullough AJ. A NASH predictive index (NPI) for use in patients with non-alcoholic fatty liver disease. Hepatology 2007; 46 (Suppl 1) 747A
  PubMedGoogle Scholar
• 92 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (4) 1072-1078
  CrossrefPubMedGoogle Scholar
• 93 Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology 2010; 51 (2) 715-717
  CrossrefPubMedGoogle Scholar
• 94 Ratziu V, Massard J, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6
  CrossrefPubMedGoogle Scholar
• 95 Angulo P, Hui J, Marchesini G , et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 849-854
  PubMedGoogle Scholar
• 96 Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57 (10) 1441-1447
  CrossrefPubMedGoogle Scholar
• 97 Guha I, Parkes J, Roderick P , et al. Noninvasive markers of fibrosis in non alcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 2009; 47: 455-460
  PubMedGoogle Scholar
• 98 Calès P, Lainé F, Boursier J , et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50 (1) 165-173
  PubMedGoogle Scholar
• 99 Kelleher T, MacFarlane C, de Ledinghen V , et al. Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis. Gastroenterology 2006; 130: A736
  PubMedGoogle Scholar
• 100 Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43 (8) 617-649
  CrossrefPubMedGoogle Scholar
• 101 Castéra L, Foucher J, Bernard PH , et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (3) 828-835
  PubMedGoogle Scholar
• 102 de Ledinghen V, Fournier C, Foucher J , et al. New Fibroscan probe for obese patients. A pilot study of feasibility and performances in patients with BMI > 30 kg/m² . J Hepatol 2009; 50 (Suppl 1) 359
  PubMedGoogle Scholar
• 103 Joka D, Wahl K, Moeller S , et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 455-464
  CrossrefPubMedGoogle Scholar
• 104 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011; 17 (29) 3377-3389
  CrossrefPubMedGoogle Scholar
• 105 Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis 2009; 13 (4) 649-665
  CrossrefPubMedGoogle Scholar
• 106 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54 (3) 603-608
  CrossrefPubMedGoogle Scholar
• 107 Tiikkainen M, Bergholm R, Vehkavaara S , et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52 (3) 701-707
  CrossrefPubMedGoogle Scholar
• 108 Suzuki A, Lindor K, St Saver J , et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43 (6) 1060-1066
  CrossrefPubMedGoogle Scholar
• 109 Promrat K, Kleiner DE, Niemeier HM , et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (1) 121-129
  CrossrefPubMedGoogle Scholar
• 110 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52 (1) 79-104
  CrossrefPubMedGoogle Scholar
• 111 Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56 (4) 944-951
  CrossrefPubMedGoogle Scholar
• 112 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50 (1) 68-76
  CrossrefPubMedGoogle Scholar
• 113 Moscatiello S, Marzocchi R, Villanova N, Bugianesi E, Marchesini G. Which treatment for nonalcoholic fatty liver disease?. Mini Rev Med Chem 2008; 8 (8) 767-775
  CrossrefPubMedGoogle Scholar
• 114 Lutchman G, Modi A, Kleiner DE , et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46 (2) 424-429
  CrossrefPubMedGoogle Scholar
• 115 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49 (1) 306-317
  CrossrefPubMedGoogle Scholar
• 116 Lavine JE, Schwimmer JB, Van Natta ML , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305 (16) 1659-1668
  CrossrefPubMedGoogle Scholar
• 117 Sanyal AJ, Chalasani N, Kowdley KV , et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
  CrossrefPubMedGoogle Scholar
• 118 Lindor KD, Kowdley KV, Heathcote EJ , et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39 (3) 770-778
  CrossrefPubMedGoogle Scholar
• 119 Yokohama S, Yoneda M, Haneda M , et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40 (5) 1222-1225
  CrossrefPubMedGoogle Scholar
• 120 Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011; 54 (5) 1631-1639
  CrossrefPubMedGoogle Scholar
• 121 Ratziu V, Sheikh MY, Sanyal AJ , et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 419-428
  CrossrefPubMedGoogle Scholar
• 122 Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22 (5) 634-638
  PubMedGoogle Scholar
• 123 Zein C, Yerian L, Cogate P , et al. Pentoxyfylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54 (5) 1610-1619
  PubMedGoogle Scholar
• 124 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles.AdultandAdolescentGL.pdf . Accessed March 1, 2012
  PubMedGoogle Scholar
• 125 Gallant JE, Staszewski S, Pozniak AL , et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292 (2) 191-201
  CrossrefPubMedGoogle Scholar